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Interleukin-11 (IL-11) up-regulates the proliferative
and invasive capacity of many cancers. Coexpression
of glycoprotein 130 (GP130) and IL-11 receptor  (IL-
11R) is necessary for high-affinity binding of IL-11 to
IL-11R. This study investigated the expression of
IL-11 and role of prostaglandin F2-F-prostanoid re-
ceptor (FP receptor) signaling in the modulation of
IL-11 expression in endometrial adenocarcinoma
cells. Localization of IL-11, IL-11R , and GP130 ex-
pression was performed by immunohistochemistry.
IL-11 and regulator of calcineurin 1 isoform 4 (RCAN1-4)
mRNA and protein expression were determined by
real-time RT-PCR and/or enzyme-linked immunosor-
bent assay/Western blot analysis using Ishikawa en-
dometrial adenocarcinoma cells stably expressing the
FP receptor (FPS cells) and endometrial adenocarci-
noma explants. IL-11 mRNA expression was signifi-
cantly elevated in endometrial adenocarcinoma samples
compared with normal endometrium and increased
with tumor grade. IL-11 protein expression localized
with FP receptor, IL-11R , and GP130 in the neoplas-
tic glandular epithelium of endometrial adenocarci-
nomas. Prostaglandin F2-FP receptor signaling sig-
nificantly elevated the expression of IL-11 mRNA and
protein in a Gq-protein kinase C-calcium-calcineurin-
nuclear factor of activated T cells-dependent manner
in FPS cells. The calcineurin signaling pathway is
known to be controlled by the RCAN (RCAN1-4). In-
deed, RCAN1-4 expression was significantly elevated
in well-differentiated endometrial adenocarcinoma
compared with normal endometrium and was found
to decrease with tumor grade and negatively regulate
IL-11 expression in vitro. This study has highlighted a
new mechanism regulating IL-11 expression in endo-
metrial adenocarcinoma cells by the FP receptor via
the calcium-calcineurin-nuclear factor of activated T
cells pathway. (Am J Pathol 2010, 176:435–445; DOI:
10.2353/ajpath.2010.090403)
Endometrial cancer is the most common female gyneco-
logical malignancy in the Western world, ranking fourth in
incidence among invasive tumors in women.1–3 Most
cases of endometrial carcinomas are sporadic estrogen-
dependent disorders that occur in pre- or postmeno-
pausal women as low-grade (well differentiated, type I)
endometrioid adenocarcinomas.4 However, 20% of tu-
mors in postmenopausal women are not estrogen depen-
dent and have a poor prognosis.1–4 In these patients,
predominantly high-grade (poorly differentiated, type II)
tumors arise either as endometrioid adenocarcinomas,
uterine papillary serous carcinomas, or clear cell carci-
nomas with a high frequency of myometrial invasion and
spread into the pelvic lymph nodes.5
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Although the mechanisms regulating endometrial ad-
enocarcinomas are still poorly defined, there is much
evidence for a role for cyclooxygenase (COX) enzymes
and prostaglandins (PGs) in uterine pathology. We and
others6,7 have demonstrated elevated expression of
COX-2, biosynthesis of PG, and elevated expression of
nuclear6 and membrane-bound G protein-coupled re-
ceptors6,8 like the F-prostanoid (FP) receptor8 in endo-
metrial adenocarcinomas. Moreover, we have shown that
elevated PGF2-FP receptor signaling, via the Gq activa-
tion of inositol-1,4,5-trisphosphate, leads to up-regulation
of tumorigenic and angiogenic genes including COX-2,9
fibroblast growth factor 2,10 and vascular endothelial
growth factor,11 indicating that PGF2-FP receptor signal-
ing can promote endometrial tumor growth by regulating
vascular function. Furthermore, FP receptor can regulate
the proliferation of endometrial epithelial cells and can
alter their adhesiveness to extracellular matrix and motil-
ity via the reorganization of the actin cytoskeleton and
activation of focal adhesion kinase.8,12,13 These findings
suggest that PGF2-FP receptor signaling plays a multi-
factorial role in regulating endometrial adenocarcinoma
by promoting an environment for angiogenesis and tissue
remodeling to facilitate tumor growth.
In addition to the regulation of cell architecture and
growth factors by the COX-PG axis, a link between PG
and chemoattractive cytokines (chemokines) such as
CXCL1 has been demonstrated in colorectal cancer,14
where PGE2 signaling has been shown to induce CXCL1
expression in colorectal cancer cells to enhance tumor
growth. Similarly in COX-2-overexpressing breast cancer
cells that had metastasized to bone, Singh et al15 have
shown recently that the pleiotropic cytokine interleukin-11
(IL-11) is significantly elevated.15 IL-11 mediates its func-
tion via the IL-11 receptor  (IL-11R). On ligand binding
to IL-11R, the glycoprotein (GP) 130 subunit, critical for
signal transduction of IL-11, is recruited to form a IL-11/
IL-11R/GP130 complex.16 Once activated, the IL-11/IL-
11R/GP130 complex can activate signal transduction
pathways17 to modulate target gene expression. IL-11
and IL-11R expression has been shown to correlate with
cellular growth, differentiation, invasiveness, tumor pro-
gression, and poor prognosis in breast and colorectal
cancer;18–20 however, the expression and regulation of
IL-11 in endometrial cancer has yet to be reported.
Here we investigated the expression profile of IL-11,
IL-11R, and GP130 in endometrial adenocarcinomas
compared with normal proliferative-phase endometrium
and its regulation in an in vitro model of endometrial
adenocarcinoma cells by PGF2 via the FP receptor.
Materials and Methods
Reagents
YM-254890 was donated by Astellas Pharma (Tsukuba,
Japan). Cyclosporin A and Inhibitor of nuclear factor of
activated T cells (NFAT)-calcineurin association-6 (Inca-
6), 4-cyano-3-methylisoquinoline, and RO-318220 were
purchased from Calbiochem (Nottingham, UK). PGF2,
AL8810, and EGTA were purchased from Sigma Chem-
ical (Dorset, UK).
Cell Line, Culture, and Treatments
Ishikawa cells engineered to stably express the full-
length human FP (PTGFR, accession no. NM_000959)
receptor to the levels observed in endometrial adenocar-
cinomas, referred to as FPS cells, were cultured as de-
scribed previously.11 FPS cells were manufactured com-
mercially, clonally selected, and verified as described in
our previous study.11 The concentrations of all chemical
inhibitors and antibodies were determined empirically by
titration using the manufacturer’s guidelines as described
in our previous studies.21,22 Cell viability in the presence
of chemical inhibitor was determined using the CellTitre
96 AQueous One Solution assay (Promega, Southamp-
ton, UK) as described previously.22 Cells were treated
with 100 nmol/L PGF2 alone or in the presence of
AL8810 (50 mol/L), YM254890 (1 mol/L), 43CMQ (1
mol/L), RO-318220 (1 mol/L), AG1478 (200 nmol/L),
cyclosporine A (1 mol/L), Inca-6 (40 mol/L), and EGTA
(1.5 mmol/L) for the time indicated. In parallel, cells
treated with vehicle and chemical inhibitor served as a
control for each treatment. Fold increase was calculated
by dividing the values obtained from the PGF2/PGF2-
inhibitor treatments by the vehicle/vehicle-inhibitor treat-
ments. All in vitro cell culture experiments were per-
formed in duplicate.
Human Tissue
Poorly differentiated (grade 3; n  10), moderately differ-
entiated (grade 2; n  10), and well-differentiated (grade
1; n  10) endometrial adenocarcinoma tissues with clin-
ical characteristics as outlined in Table 1 were collected
from women undergoing hysterectomy and who had
been prediagnosed on endometrial biopsy to have endo-
metrial adenocarcinoma of the uterus of the endometrioid
type. The patients had received no treatment before sur-
gery. All patients were postmenopausal women with ages
that ranged between 50 and 71 years of age and pre-
sented with complaint of postmenopausal bleeding. The
median age of all patients in our study was 60.5 years.
Total abdominal hysterectomy specimens with bilateral
salpingo-oophorectomy for adenocarcinoma were col-
lected from the operating theater and placed on ice. With
minimal delay, the specimens were opened by a gyne-
cological pathologist. Small samples (5 mm to 3 cm) of
polypoidal adenocarcinoma tissue were collected from
the endometrial lumen. Tissue samples were transferred
into neutral-buffered formalin (for paraffin wax embed-
ding for immunohistochemistry and immunofluorescence
studies), snap-frozen in dry ice and stored at 70°C (for
RNA extraction), and placed in RPMI 1640 culture me-
dium containing 2 mmol/L L-glutamine, 100 U of penicillin,
100 g/ml streptomycin, and 8.4 mol/L indomethacin (to
inhibit endogenous COX activity) for ex vivo explant cul-
tures. The diagnosis of endometrial adenocarcinoma was
confirmed histologically in all cases as defined in Table 1
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and the percentage of tumor cells to stroma was esti-
mated to be not less than 75%:25%. Normal endome-
trium from the proliferative phase of the menstrual cycle,
with clinical parameters as outlined in Table 2 (n  10),
was collected with an endometrial suction curette from
women undergoing surgery for gynecological proce-
dures including surgical sterilization or abnormal uterine
bleeding in whom histological examination of endometrium
was normal with no underlying endometrial pathology
(Pipelle, Laboratoire CCD, Paris, France). This phase of the
menstrual cycle was chosen as a comparator for the
endometrial cancer samples as it exhibits all of the hall-
marks of endometrial tumorigenesis, namely low proges-
terone levels, rapid cellular proliferation, differentiation
and tissue remodeling and is the phase of the menstrual
cycle with the highest expression of FP receptor.13 All
women had regular menstrual cycles (25 to 35 days) and
the tissue collected was processed exactly as described
above. The ages of the control women ranged from 21 to
39 years of age with a median age of 30.5 years. None of
the control women had received a hormonal preparation
in the 3 months preceding biopsy collection. Biopsies
were dated according to stated last menstrual period and
confirmed by histological assessment according to the
criteria of Noyes et al.23 Ethical approval was obtained
from Lothian Research Ethics Committee, and written
informed consent was obtained from all subjects before
tissue collection.
TaqMan Quantitative RT-PCR
Total RNA was extracted from FPS cells and proliferative-
phase endometrium (n  10; samples 1 to 10 in Table 2),
poorly differentiated (n  10; samples 1 to 10 in Table 1),
moderately differentiated (n  10; samples 11 to 20 in
Table 1), and well-differentiated (n  10; samples 21 to
30 in Table 1) adenocarcinoma tissues using Total RNA
Isolation Reagent (Abgene, Epsom, UK), according to
the manufacturer’s instruction. Tissue lysis was per-
formed using a tissue lyser (Qiagen, Crawley, UK). Quan-
tified RNA samples were reverse transcribed, and quan-
titative RT-PCR was performed as described before8
using the following primers and probes: IL-11, forward,
5-CCCAGTTACCCAAGCATCCA-3, and reverse, 5-
AGACAGAGAACAGGGAATTAAATGTGT-3, and probe,
5-FAM-CCCCAGCTCTCAGACAAATCGCCC-3; IL-
11R, forward, 5-CCAGCCAGATCAGCGGTTTA-3, and
reverse, 5-TGGCTATCAGCTCCTAGGACTGT-3, and
probe, 5-FAM-CCACCCGCTACCTCACCTCCTACAGG-
3; and GP130, forward, 5-CTGAATGGGCAACACA-
CAAGTT-3, and reverse, 5-CCAGACTTCAATGTTGA-
CAAAATACA-3, and probe, 5-FAM-CAAAGCAAAA-
CGTGACACCCCCACC-3. Primers and data were ana-
lyzed and processed using Sequence Detector version
1.6.3 (Applied Biosystems, Warrington, UK). Expression
of analyzed genes was normalized to RNA loading for
each sample using the 18S ribosomal RNA as an internal
standard. Results are expressed either as relative mRNA
expression or as fold increase above vehicle-treated
cells. Data are presented as mean  SEM Cell culture
experiments were repeated three times in duplicate.
Immunohistochemistry
Immunohistochemistry for IL-11, IL-11R, and GP130 was
performed using poorly (n 10; samples 1 to 10 in Table 1),
moderately (n  10; samples 11 to 20 in Table 1), and
well-differentiated (n  10; samples 21 to 30 in Table 1)
endometrial adenocarcinomas and proliferative-phase
endometrium (n  10; Table 2) using the Vision Biosys-
Table 1. Clinical Parameters and Tumor Characteristics for
Poorly (Poor, n  10), Moderately (Mod, n  10),
and Well-Differentiated (Well, n  10) Endometrial
Adenocarcinomas
Sample no. Grade FIGO stage
1 Poor Ia
2 Poor IIIa
3 Poor Ib
4 Poor Ib
5 Poor IIIa
6 Poor Ib
7 Poor Ib
8 Poor IIIa
9 Poor IIIa
10 Poor IIb*
11 Mod Ib
12 Mod Ic
13 Mod IIb*
14 Mod IIIa
15 Mod Ic
16 Mod Ic
17 Mod Ic
18 Mod Ia
19 Mod Ib
20 Mod IIb
21 Well Ib
22 Well Ib
23 Well Ia
24 Well Ic
25 Well IIIa
26 Well Ib
27 Well Ib
28 Well Ib
29 Well Ia
30 Well Ia
All endometrial adenocarcinomas studied were of pure or predominantly
of endometrioid type. There were no pure serous or clear cell subtypes in
the series, and none of the tumors showed carcinosarcoma. In these two
samples myometrial invasion was 50%.
Table 2. Clinical Parameters for Normal Endometrial Samples
from Proliferative-Phase Endometrium (n  10)
Sample
no. Histology
Progesterone
(nmol/)L
Estradiol
(pmol/L)
1 Proliferative 4.26 339.38
2 Proliferative 2.22 641.37
3 Proliferative 4.62 525.00
4 Proliferative 4.57 495.00
5 Proliferative 2.82 214.00
6 Proliferative 1.78 400.00
7 Proliferative 4.80 204.00
8 Proliferative 3.12 731.00
9 Proliferative 2.32 1796.00
10 Proliferative 0.17 989.70
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tems Bond Immunostaining Robot (Leica Microsystems,
Wetzlar, Germany) as described previously.7,8,10 Control
sections were incubated with equivalent concentration of
normal IgG from host species.
Immunofluorescence and Confocal Laser
Microscopy
Colocalization of FP receptor, IL-11R, and IL-11 protein
expression was investigated using a random selection of
tissues from patient samples as outlined in Tables 1 and
2, comprising normal proliferative (n  5; samples 1 to 5
in Table 2) and well-differentiated endometrial cancer
tissues (n  4; samples 21 to 24 in Table 1). Five-
micrometer paraffin wax-embedded tissue sections were
cut and mounted onto coated slides. Sections were de-
waxed in xylene, rehydrated in graded ethanol, and
washed in water. Antigen retrieval was performed by
pressure cooking the slides for 5 minutes in 0.01 M
sodium citrate (pH 6). After antigen retrieval, endoge-
nous endoperoxidase activity was blocked by incubat-
ing slides in methanol containing 3% H2O2. For the
triple immunofluorescence, sections were blocked in
normal goat serum (NGS) and incubated overnight with
a polyclonal anti-IL-11R antibody at 1/600 (C-20; Santa
Cruz Biotechnology, Santa Cruz, CA). Sections were
washed, incubated in goat anti-rabbit peroxidase (1/500
in NGS for 30 minutes), followed by fluorochromes tissue
specific antigen-plus cyanide 3 (1/50 in diluent for 10
minutes; PerkinElmer, Wellesley, MA; Applied Biosys-
tems). Sections were washed, and antigen retrieval in
citrate buffer and blocking in NGS was repeated before
being incubated overnight with a polyclonal anti-FP re-
ceptor antibody at 1/600 (Cayman Chemical, Ann Arbor,
MI). Sections were washed, incubated in goat anti-rabbit
peroxidase (1/500 in NGS), followed by fluorochromes
tissue specific antigen-plus cyanide 5 (1/50 in diluent).
Finally, after further antigen retrieval and blocking steps,
sections were incubated overnight with a monoclonal
anti-IL-11 antibody at 1/100 (R&D Systems, Oxford, UK).
Sections were washed, incubated in goat anti-mouse
peroxidase (1/500 in NGS), followed by fluorochromes
tissue specific antigen-plus flourescein (green) (1/50 in
diluent). All sections were washed, mounted in Per-
mafluor, and visualized using a laser-scanning micro-
scope (meta confocal; Carl Zeiss, Jena, Germany).
Matched serial control sections from each tissue were
incubated with equivalent concentration of normal IgG
from host species.
Enzyme-Linked Immunosorbent Assay
Secreted IL-11 was quantified using an in-house enzyme-
linked immunosorbent assay (ELISA). IL-11 was mea-
sured by ELISA using matched pairs of capture and
biotinylated labeled detection antibodies for IL-11 (R&D
Systems). Briefly, plates were coated overnight at 4°C
with capture antibody added at 100 l/well, followed by
100 l/well of coating solution for 1 hour at room temper-
ature. The coating solution was removed and the plates
stored at 20°C. Before use, the plates were washed
twice in wash buffer (0.05% Tween 20, 10 mmol/L Tris,
and 0.15 M NaCl). Recombinant IL-11 standard (R&D
Systems) was diluted in ELISA buffer (using a concentra-
tion range of 4000 to 31.25 pg/ml), and 100 l of standard
or conditioned media sample was added per well in
duplicate. Plates were incubated overnight at 4°C and
then washed four times as above, before addition of
anti-IL-11 detection antibody (R&D Systems) at 100 ng/ml
in ELISA buffer. Plates were again washed four times
before addition of streptavidin–peroxidase at 1/2000
adding 100 l/well for 20 minutes at room temperature on
a rocker. Plates were again washed four times before
addition of tetramethylbenzidine substrate. Color change
was monitored and stopped using 2 N sulfuric acid.
Plates were read on a plate reader at 450 nm within 10
minutes of quenching. Samples were serially diluted be-
fore assay, and the concentration of IL-11 in each sample
was interpolated from the within plate standard curve.
The minimum detection limit was 16 pg/ml. The interas-
say and intra-assay coefficient of variance were 7.31 and
6.04%, respectively. Data are represented as mean 
SEM for four individual experiments.
Western Blot Analysis
Proteins were extracted and quantified as described pre-
viously.8 Samples were loaded in duplicate. In parallel,
cell lysate from Ishikawa cells infected with full-length
regulator of calcineurin 1–4 (RCAN1-4) adenovirus as
described by Maldonado-Perez et al21 was used as a
positive control (data not shown). After resolving and
immunoblotting, membranes were incubated overnight at
4°C, with a rabbit anti RCAN1-4 antibody (1/5000), a gift
from Dr. E. W. Bush (Myogen, Westminster, CO), together
with a mouse anti--actin antibody (1/800) (Santa Cruz
Biotechnology). The following day, cells were washed
and incubated with goat anti-rabbit Alexafluor 680 (1/
5000; Invitrogen, Carlsbad, CA) and goat anti-mouse
IRDye 800 (1/5000; Rockland, Gilbersville, PA) for 60
minutes at room temperature. Blots were visualized and
the protein immunoreactivity quantified using an Odyssey
infrared imaging system (LI-COR, Cambridge, UK).
RCAN1-4 relative density was calculated by dividing the
value obtained for RCAN1-4 by the value obtained for
-actin and expressed as fold above vehicle controls.
Data are presented as mean  SEM from three indepen-
dent experiments.
Adenovirus Infection
The RCAN adenovirus was constructed using the cDNA
of RCAN1-4 (Origene, Rockville, MD) as detailed in our
previous study.21 Ishikawa FPS cells were plated in 5-cm
dishes or 6-well plates at a density of 200,000 cells/well.
Thereafter, cells were infected with RCAN1-4 adenovirus
at a multiplicity of infection of five viruses per cell. In
parallel, cells were infected with a negative control ade-
novirus containing a cytomegalovirus promoter with no
insert (Rad60)24 at the same multiplicity of infection. For
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RCAN infection of endometrial adenocarcinoma tissues,
four poorly differentiated tissues (samples 1 to 4; Table 1)
were used. The tissues were processed in the order in
which they were received from the gynecology clinic
without bias toward clinical parameters such as Interna-
tional Federation of Gynecology and Obstetrics (FIGO)
stage or depth of invasion. Tissues were prepared for
infection by finely sectioning using a sterile scalpel blade
and incubated with 1  106 virus/ml of either the RAD60
or RCAN1-4 adenovirus. Cells and tissues were incu-
bated with virus for 24 hours and serum starved overnight
before treatment with vehicle or 100 nmol/L PGF2. All
infections and treatments were conducted in duplicate.
Data are presented as mean  SEM (from four indepen-
dent experiments for in vitro cell culture and n  4 for
adenocarcinoma explants).
Statistical Analysis
The data in this study were analyzed by unpaired t-test or
analysis of variance (ANOVA) to compare groups using
Microsoft Excel (Microsoft) and Prism 4.0c (GraphPad,
San Diego, CA) with an additional posttest to assess the
evidence of a linear trend across grades of adenocarci-
nomas where appropriate. Values of P  0.05 were con-
sidered significant.
Results
IL-11, IL-11R, and GP130 Expression in
Endometrial Adenocarcinoma and Normal
Proliferative-Phase Endometrium
The relative mRNA expression of IL-11 (Figure 1A), its
receptor IL-11R (Figure 1B), and its coreceptor GP130
(Figure 1C) was investigated in human endometrial ade-
nocarcinoma and normal proliferative-phase endome-
trium by TaqMan quantitative RT-PCR analysis. The ex-
pression of IL-11 mRNA (Figure 1A) was significantly
up-regulated in all endometrial adenocarcinomas repre-
sented in Table 1 irrespective of grade or FIGO stage,
compared with normal proliferative-phase endometrial
tissues listed in Table 2 (t-test, prolif versus Poor P 
0.001; t-test, prolif versus Mod P  0.005; t-test, prolif
versus well P  0.02). In addition, a significant linear
trend was observed across the different grades of cancer
for IL-11 mRNA with highest levels of expression ob-
served in poorly differentiated cancer (, ANOVA posttest
for linear trend; P  0.0001). Expression of IL-11R (Fig-
ure 1B) and GP130 (Figure 1C) was significantly de-
creased in all endometrial adenocarcinomas represented
in Table 1 compared with normal proliferative-phase en-
dometrium listed in Table 2 (t-test, prolif versus Poor P 
0.03; t-test, prolif versus Mod P  0.04; t-test, prolif
versus well P  0.04) and did not appear to vary with
tumor grade or FIGO stage.
The site of IL-11, IL-11R, and GP130 protein expres-
sion in endometrial adenocarcinomas was determined by
immunohistochemistry (Figure 2). Strong apical and
baso-lateral immunoreactive staining was observed for
IL-11 (Figure 2, A, D, and G), IL-11R (Figure 2, B, E, and
H), and GP130 (Figure 2, C, F, and I) in the glandular
epithelium and vascular endothelium (BV, Figure 2, M–O,
as indicated by the arrow; representative sample 29;
Table 1) of poorly differentiated (representative sample 2;
Table 1), moderately differentiated (Mod, representative
sample 15; Table 1), and well-differentiated (representa-
tive sample 26; Table 1) endometrial adenocarcinomas
with stromal staining observed for all three biomarkers.
The expression patterns of IL-11, IL-11R, and GP130
were similar within each respective grade irrespective of
clinical parameter outlined in Table 1. The pattern of
staining for IL-11, IL-11R, and GP130 was similar in
endometrial adenocarcinomas to that observed for nor-
mal proliferative endometrium (Figure 2, J–L). IL-11 local-
ized to the apical surface (dark arrow) with punctuate
lateral and basal (white arrow) surface staining (Figure
2J, representative sample 2; Table 2) in proliferative-
phase endometrium with low levels of staining observed
for IL-11 in the stroma. IL-11R exhibited higher intensity
of staining on the apical (dark arrow) compared with
Figure 1. IL-11, IL-11R, and GP130 mRNA expression. A: The relative mRNA expression of IL-11 in normal proliferative-phase endometrium (n 10) and poorly
(n  10), moderately (n  10), and well-differentiated (n  10) endometrial adenocarcinoma as determined by real-time quantitative RT-PCR analysis. Data are
represented as mean  SEM proliferation is significantly different from poorly (*P  0.001), moderately (**P  0.005), and well-differentiated (***P  0.02)
adenocarcinomas compared with proliferative-phase endometrium; ANOVA posttest for linear trend for IL-11 expression between poorly, moderately, and
well-differentiated adenocarcinomas, ****P  0.0001. The relative mRNA expression of IL-11R (B) and GP130 (C) in normal proliferative-phase endometrium
(n 10) and poorly (n 10), moderately (n 10), and well-differentiated (n 10) endometrial adenocarcinoma as determined by real-time quantitative RT-PCR
analysis. Data are represented as mean  SEM proliferation is significantly different from poorly (*P  0.03), moderately, and well-differentiated (**P  0.04)
adenocarcinomas compared with proliferative-phase endometrium.
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basal or lateral surfaces (Figure 2K, representative sam-
ple 2; Table 2) with greater intensity of staining observed
in the stroma compared with IL-11. GP130 immunoreac-
tivity was localized to the apical and baso-lateral surfaces
of the luminal and glandular epithelium with stromal re-
activity, which was greater than that observed for IL-11 or
IL-11R (Figure 2L, representative sample 2; Table 2).
Incubating sections with nonimmune IgG from the host
species showed no immunoreactivity (inset shown; Fig-
ure 2L). Furthermore, the expression of FP receptor (Fig-
Figure 2. Localization of the site of expression
of IL-11, IL-11R, and GP130 in endometrial ad-
enocarcinomas and normal proliferative endo-
metrium. The site of expression of IL-11 (A, D,
G, J, and M), IL-11R (B, E, H, K, and N), and
GP130 (C, F, I, L, and O) in samples of poorly
(poor, A–C, representative sample 2; Table 1),
moderately (mod, D–F; representative sample
15; Table 1), and well-differentiated (G–I, repre-
sentative sample 26; Table 1) endometrial ade-
nocarcinomas and proliferative-phase endome-
trium (J–L, representative sample 2; Table 2) by
serial section. Intense immunoreactivity as indi-
cated by the brown 3,3-diaminobenzidine stain-
ing was observed to be localized to the glandular
epithelial and vascular compartment (BV, M–O
as indicated by the arrow, representative sam-
ple 29; Table 1) with diffuse stromal immunore-
activity in all tissue sections with no discernable
difference in staining pattern observed within
each grade or stage of adenocarcinoma. IL-11
and IL-11R displayed distinct immunoreactivity
on the apical surface in proliferative-phase en-
dometrium (black arrow for IL-11 and IL-11R,
J and K, respectively) with lesser punctuate
staining on the basal (white arrow, for IL-11, J)
and lateral surfaces. Control sections were neg-
ative for immunoreactivity (Inset, representative
serial section of L, representative sample 2; Ta-
ble 2). Scale bar  50 mol/L.
A  Proliferative B  Well differentiated Adenocarcinoma
A B
C D
C  Negative Control
Figure 3. Colocalization of expression of FP receptor, IL-11, and IL-11R in well-differentiated endometrial adenocarcinoma and proliferative-phase endome-
trium. Colocalization of the expression of FP receptor (A and B, lower left panel, blue channel), IL-11R (A and B, upper right panel, red channel), and IL-11
protein (A and B, upper left panel, green channel) colocalized (A and B, lower right panel, merged purple channel) in the glandular epithelium and vascular
endothelium in proliferative-phase endometrium (A, representative sample 9; Table 2) and well-differentiated endometrial adenocarcinoma (B, representative
sample 27; Table 1) by immunofluorescence. The control section C (representative of serial section of representative sample 9; Table 2) was negative for
immunoreactivity for all three markers. Scale bar  50 mol/L.
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ure 3, A and B, lower left panel, blue channel), IL-11R
(Figure 3, A and B, upper right panel, red channel), and
IL-11 protein (Figure 3, A and B, upper left panel, green
channel) colocalized (Figure 3, A and B, lower right
panel, merged purple channel) in glandular epithelium
and vascular endothelium in proliferative-phase endome-
trium (Figure 3A, representative sample 9; Table 2) and
well-differentiated endometrial adenocarcinoma (Figure
3B, representative sample 27, Table 1) by immunofluo-
rescence. The control section (Figure 3C, representative
of serial section sample 9; Table 2) was negative for
immunoreactivity for all three biomarkers.
PGF2-FP Receptor Activation Induces IL-11
Expression and Release in Ishikawa FPS Cells
Because FP receptor, IL-11, and IL-11R colocalized in
the glandular epithelium in endometrial adenocarcino-
mas, PGF2 signaling to IL-11 was investigated using a
human endometrioid endometrial adenocarcinoma cell
line stably transfected with the FP receptor (Ishikawa FPS
cells).11 FPS cells were stimulated with vehicle or 100
nmol/L PGF2 for the times indicated in the figure legend.
PGF2 stimulation resulted in a significant time-depen-
dent increase in the relative expression of IL-11 mRNA
(Figure 4A, ANOVA, P  0.001) and protein in FPS cells
(Figure 4B, ANOVA, P  0.001), with maximal responses
observed after 16 and 72 hours, respectively. In contrast,
PGF2-FP receptor stimulation of FPS cells promoted a
significant time-dependent down-regulation of IL-11R
mRNA expression compared with control (Figure 4C,
t-test, P  0.04, 0.03, and 0.03 for 8, 12 and 16 hours,
respectively). No significant alteration in mRNA expres-
sion of GP130 was observed in FPS cells in response to
PGF2-FP receptor activation (data not shown).
PGF2-FP Receptor Activation Induces
the Expression of IL-11 via the
Calcineurin-NFAT Pathway
The signal transduction pathways mediating PGF2-FP
receptor signaling to IL-11 were investigated. FPS cells
were stimulated with vehicle or 100 nmol/L PGF2 for 24
hours. In parallel, cells were also treated with vehicle or
PGF2 in the presence of the FP receptor antagonist
AL8810 or chemical inhibitors of Gq/11 (YM254890), pro-
tein kinase (PK)C (RO-318220), PKA (4-cyano-3-methyli-
soquinoline), calcineurin (cyclosporine A), NFAT (Inca-6),
or calcium chelator EGTA. Treatment of FPS cells with
PGF2 promoted a significant increase in IL-11 mRNA
(Figure 5A, t-test P  0.01) and protein expression (Fig-
ure 5B, t-test P  0.01). Cotreatment of FPS cells with FP
receptor antagonist AL8810 (t-test P  0.001) or chemi-
cal inhibitors of Gq/11 (YM254890; t-test, P  0.02), PKC
(RO-318220; t-test, P  0.01), calcineurin (cyclosporine
A; t-test P  0.03), NFAT (Inca-6; t-test, P  0.03), or
calcium chelator EGTA (P  0.03) but not PKA (4-cyano-
3-methylisoquinoline; t-test, P  0.12) significantly inhib-
ited the expression of IL-11 mRNA (Figure 5A) and re-
lease of IL-11 protein (Figure 5B). These data indicate
that IL-11 expression and release is regulated via the
PGF2-FP receptor activation of the Gq-PKC-calcium-
calcineurin-NFAT signal transduction pathway.
Having identified that the PGF2-FP receptor activation
of IL-11 was mediated via the calcineurin-NFAT signaling
pathway, the regulation of IL-11 by the RCAN1, previ-
ously known as Down syndrome critical region gene 1 or
Adapt 78, which is known to endogenously modulate
calcineurin-NFAT signaling25 was explored. RCAN1 iso-
form 4 (RCAN1-4) is known to bind to calcineurin and
inhibit activation of NFAT when overexpressed26 and
has been shown by our laboratory to be a negative
regulator of chemokine expression.21 The temporal
regulation of RCAN1-4 in FPS cells by PGF2 was
investigated by quantitative RT-PCR and Western blot
analysis. Treatment of FPS cells with 100 nmol/L PGF2
resulted in rapid time-dependent induction of RCAN1-4
mRNA (Figure 5C; ANOVA, P  0.001) and protein
(Figure 5D; ANOVA, P  0.001), with maximal expres-
sion after 4 hours with subsequent reduction to basal
level. The reciprocal nature of RCAN1-4 expression
compared with IL-11 (Figure 4, A and B) suggested
that it could be a negative regulator of IL-11 expres-
sion. To investigate this, an adenoviral construct ex-
pressing the full-length RCAN1-4 cDNA was used. FPS
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analysis and ELISA, respectively. Data are represented as mean  SEM *P  0.001 for PGF treatment compared with control treatment. C: IL-11R mRNA
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compared with control treatment.
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cells were infected with either a control (RAD60) ade-
novirus or RCAN1-4 adenovirus for 24 hours before
stimulation or left uninfected. Cells were stimulated
with vehicle or 100 nmol/L PGF2 for 24 hours. Over-
expression of RCAN1-4 in FPS cells significantly re-
duced the PGF2-FP receptor-mediated induction of
IL-11 mRNA expression (Figure 5E; t-test, P  0.03) and
protein secretion (Figure 5F; t-test, P  0.02) compared
with cells infected with the control virus or control cells,
which were uninfected.
Expression and Regulation of RCAN1-4 in
Endometrial Tissues
Because PGF2-FP receptor signaling to IL-11 was reg-
ulated by RCAN1-4, the mRNA expression of RCAN1-4
(Figure 6A) in human endometrial adenocarcinoma com-
pared with normal proliferative-phase endometrium was
investigated by quantitative RT-PCR analysis. RCAN1-4
expression was significantly higher in well-differentiated
adenocarcinoma compared with normal proliferative
phase endometrium (t-test P  0.03). Interestingly, we
observed a significant linear trend for RCAN1-4 mRNA
expression, which decreased with increasing tumor
grade, such that RCAN1-4 mRNA expression was signif-
icantly lower in poorly differentiated endometrial adeno-
carcinomas (Figure 6A, ANOVA, posttest for linear trend,
P  0.002).
Figure 5. IL-11 is regulated by PGF2 via the calcium-calcineurin-NFAT
pathway. IL-11 mRNA expression (A) and protein secretion (B) in FPS
cells treated for 24 hours, respectively, with vehicle, 100 nmol/L PGF2
(P  0.01), 100 nmol/L PGF2 in the absence/presence of AL8810 (50
mol/L; P  0.001), YM254890 (1 mol/L; P  0.02), RO-318220 (1
mol/L; P  0.01), 4-cyano-3-methylisoquinoline (4C3MQ) (1 mol/L;
P  0.12), EGTA (1.5 mmol/L; P  0.03), cyclosporine A (CsA) (1 mol/L;
P  0.03), or Inca-6 (40 mol/L; P  0.03) as determined by quantitative
RT-PCR analysis and ELISA, respectively. Data are represented as mean 
SEM; PGF treatment is significantly different from PGF and inhibitor
treatment or PGF and vehicle control treatment at the previously listed
values. RCAN1-4 mRNA (C) and protein expression (D) in FPS cells
treated with 100 nmol/L PGF2 for 2, 4, 6, 8, 24, 48, and 72 hours as
determined by quantitative RT-PCR and Western blot analysis, respec-
tively. Data are represented as mean  SEM, *P  0.001 for PGF treatment
compared vehicle control treatment at each time point. E: FPS cells were
infected with either RAD60 control adenovirus or RCAN1-4 adenovirus for
24 hours or left uninfected. Cells were then treated with vehicle or 100
nmol/L PGF2 for 24 hours and IL-11 mRNA, and protein expression (F)
was determined by quantitative RT-PCR analysis and ELISA, respectively.
Data are represented as mean  SEM for PGF treatment compared with
vehicle control treatment for mRNA (E, *P  0.03) and protein (F, *P 
0.02).
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Figure 6. RCAN1-4 expression in endometrial tissues. A: Relative mRNA
expression of RCAN1-4 in normal proliferative-phase endometrium (n  10)
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endometrial adenocarcinoma as determined by real-time quantitative RT-PCR
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entiated adenocarcinomas; **P  0.002. B: Poorly differentiated endometrial
adenocarcinomas explants (samples 1 to 4; Table 1) were infected with either
RAD60 control adenovirus or RCAN1-4 adenovirus for 24 hours and then
stimulated with vehicle or 100 nmol/L PGF2 for 24 hours and subjected to
quantitative RT-PCR analysis for IL-11 mRNA expression. Data are repre-
sented as mean SEM ***P 0.003 for PGF treatment compared with vehicle
control treatment. C: A schematic summary. PGF2-FP receptor activation in
endometrial adenocarcinoma cells promotes the induction of RCAN1-4 and
IL-11 via the Gq-phospholipase C-PKC-calcium (Ca2	)-calcineurin-NFAT
cascade. RCAN1-4 is temporally activated in a reciprocal manner to IL-11 by
PGF-FP receptor signaling and acts as a negative regulator of the calcineurin
pathway to regulate IL-11 expression.
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RCAN1-4 Is a Negative Regulator of IL-11
Expression in Endometrial Adenocarcinoma
Explants
Finally, the role of RCAN1-4 as a negative regulator of
IL-11 in endometrial adenocarcinomas was investi-
gated ex vivo. Four poorly differentiated endometrioid
endometrial adenocarcinoma explants (samples 1 to 4;
Table 1) were infected with either a control (RAD60)
adenovirus or RCAN1-4 adenovirus for 24 hours before
stimulation with vehicle or 100 nmol/L PGF2 for 24
hours (Figure 6B). Overexpression of RCAN1-4 in these
endometrial adenocarcinoma samples significantly re-
duced the PGF2-FP receptor-mediated induction of IL-11
mRNA expression in explants compared with control virus-
infected tissue (t-test, P  0.003).
Discussion
IL-11 has been shown to regulate cell motility, invasion,
and metastasis in vitro and in vivo.15, 20, 27, 28 The present
study demonstrated elevated expression of IL-11 in en-
dometrial adenocarcinomas compared with normal en-
dometrium from the proliferative phase of the menstrual
cycle. As the endometrium of postmenopausal women is
no longer under normal hormonal control, the tissue is
atrophic and often not attainable for analysis, we chose
normal proliferative-phase endometrium as our compar-
ator. This is the phase of the menstrual cycle that exhibits
rapid cellular proliferation, differentiation, and tissue re-
modeling and is the phase of the menstrual cycle with the
highest expression of FP receptor.13 Interestingly, the
present study highlights a significant variation in expres-
sion of IL-11 with grade of adenocarcinomas, with high-
est levels observed in high-grade (poorly differentiated)
adenocarcinomas. Furthermore, IL-11 and IL-11R pro-
tein expression colocalized with FP receptor expression
in normal endometrial tissue and endometrial adenocar-
cinomas. The pattern of expression of IL-11, IL-11R, and
its coreceptor GP130 was similar in endometrial adeno-
carcinoma compared with normal proliferative-phase en-
dometrium in the present study confirming the localiza-
tion of these biomarkers as reported by others in normal
endometrium29–32 and other carcinomas.33,34 Moreover,
we have shown that IL-11 is regulated by PGF2 via the
FP receptor in an in vitro model system of endometrial
adenocarcinoma cells and poorly differentiated endome-
trial adenocarcinoma explants ex vivo. To our knowledge,
this is the first study to report on the expression, localiza-
tion, and cellular mechanism regulating IL-11 in endome-
trial adenocarcinomas.
Although little is known of the role of IL-11 in endome-
trial cancer, IL-11 is essential for normal reproduction in
the human and mouse.35,36 IL-11 and IL-11R expres-
sion are dysregulated in endometrium of infertile women
with endometriosis,35,36 and IL-11 in the normal endome-
trium is known to promote the migration of trophoblast
cells.27 IL-11 and IL-11R have been shown to correlate
with tumor progression, cellular growth and differentia-
tion, and poor prognosis in breast and colorectal can-
cers18,19 and is associated with breast cancer cell me-
tastases to bone.15 To investigate the regulation of IL-11,
IL-11R, and GP130 in endometrial adenocarcinomas by
the FP receptor, we used Ishikawa FPS cells, stably ex-
pressing the FP receptor. This in vitro approach has pre-
viously been used by our laboratory and others to inter-
rogate PGF2-FP receptor signaling.
10,11,37–39 Using this
model system, we have previously demonstrated that the
PGF2-FP receptor signaling in Ishikawa FPS cells paral-
lels the ex vivo effects of PGF2 on endometrial adeno-
carcinoma explants, indicating that it is a suitable model
system to interrogate FP receptor signaling in endome-
trial epithelial cells in vitro.10,11
Here we have demonstrated that PGF2 promotes the
synthesis and release of IL-11 in Ishikawa FPS cells in a
time-dependent manner. We confirmed that PGF2-FP
receptor signaling regulated IL-11 mRNA expression ex
vivo using endometrial adenocarcinoma explants. Inter-
estingly, PGF2-FP receptor interaction promoted a time-
dependent decrease in the mRNA expression of IL-11R
in Ishikawa FPS cells, suggesting that a negative feed-
back loop was being activated to prevent autocrine in-
duction of the IL-11R/GP130 receptor complex by IL-11.
Because expression of IL-11R mRNA is significantly
reduced in endometrial adenocarcinomas compared
with normal proliferative-phase endometrium, it is feasi-
ble that activation of the FP receptor in adenocarcinomas
in vivo could down-regulate expression of the IL-11R
mRNA in a similar manner to our observation with the
Ishikawa FPS cell line in vitro. We investigated whether
the mechanism of down-regulation of IL-11R in vitro was
mediated via IL-11; however, treatment of FPS cells with
the recombinant IL-11 had no effect on IL-11R mRNA
expression (data not shown), indicating that either PGF2
was having a direct inhibitory effect on IL-11R mRNA
synthesis or another factor produced by PGF2-FP recep-
tor signaling was regulating IL-11R mRNA in Ishikawa
FPS cells in vitro.
The intracellular signal transduction pathways mediat-
ing the role of the FP receptor in regulating IL-11 was
investigated using chemical inhibitors of intracellular sig-
naling. IL-11 was found to be regulated in FPS cells at the
mRNA and protein level by PGF2 via the PKC-calcium-
calcineurin-NFAT signaling pathway. NFAT activation by
calcineurin, which mediates its dephosphorylation and
translocation to the nucleus, is known to be regulated by
the RCAN.25 RCAN1-4 is known to bind to calcineurin,
and previous studies have shown that overexpression of
this protein results in an inhibition of calcineurin activation
of NFAT.26,40,41 The temporal pattern of expression of
RCAN1-4 mRNA and protein in FPS cells was investi-
gated in response to PGF2 and found to be regulated in
a reciprocal manner to IL-11, reaching a peak of expres-
sion that preceded IL-11  8 hours, suggesting that
RCAN1-4 could act as a negative regulator of IL-11 ex-
pression. Indeed, overexpression of RCAN1-4 and sub-
sequent inhibition of NFAT activation significantly inhib-
ited the PGF2-mediated activation and release of IL-11
from FPS cells. This is in agreement with other published
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observations that show that expression of this isoform is
induced by NFAT41 and can negatively regulate chemo-
kines, such as IL-8, in endometrial epithelial cells.21
Dysregulated RCAN (also called Down syndrome can-
didate region 1) expression has been linked to patholog-
ical processes. For example, RCAN overexpression in
brains of Down syndrome fetuses40 and Alzheimer’s pa-
tients42 is thought to enhance neurodegenerative condi-
tions. RCAN expression is known to be up-regulated by
glucocorticoids43 and is induced in endothelial cells as a
negative feedback regulator of endothelial cell prolifera-
tion and branching.41,44 We investigated the expression
of RCAN1-4 in normal proliferative-phase endometrium
and endometrial adenocarcinomas. We found signifi-
cantly lower RCAN1-4 expression with advancing tumor
grade, such that levels of RCAN1-4 were lowest in high-
grade (poorly differentiated) adenocarcinomas, the
opposite pattern to that seen for IL-11 expression. Fur-
thermore, RCAN1-4 overexpression could negatively reg-
ulate IL-11 expression in cancer explants ex vivo similarly
to our observations using the Ishikawa FPS cell line in
vitro. Although we found no difference within each grade
with respect to FIGO stage, our data show that RCAN1-4
expression reduces coincident with advancing grade of
endometrial adenocarcinoma (ie, from well-differentiated
or low-grade to poorly differentiated or high-grade can-
cer). These findings suggest that the natural brake
created by RCAN1-4 to control calcineurin signaling
and cytokine production is defective in high-grade
(poorly differentiated) compared with low-grade (well-
differentiated) adenocarcinomas. This results in unop-
posed PGF2-FP receptor signaling via the calcium-
calcineurin-NFAT pathway to elevate cytokine production
such as IL-11 and may confer an advantage to tumor
progression and metastasis. However, further studies
are needed to determine the prognostic and/or predic-
tive value of IL-11, RCAN1-4, and the calcineurin-NFAT
pathway in women with early or advanced endometrial
adenocarcinoma.
In conclusion, these data (as summarized in Figure
6C) show that PGF2-FP receptor activation in endome-
trial adenocarcinoma cells regulates IL-11 expression via
the Gq-phospholipase C-PKC-calcium-calcineurin-NFAT
pathway. Moreover, RCAN1-4 was identified as a negative
regulator of PGF2-FP receptor-mediated IL-11 expression
in endometrial adenocarcinoma cells stably expressing the
FP receptor in vitro and tissue explants ex vivo. Further
studies to evaluate whether RCAN signaling can be ex-
ploited therapeutically to negatively control calcineurin-
NFAT signaling, and IL-11 production may be of potential
clinical significance for women with type 11 high-grade
(poorly differentiated) endometrial adenocarcinoma.
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